Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
DaVita ( (DVA) ) has provided an announcement.
On July 17, 2025, DaVita Inc. entered into a Seventh Amendment to its Credit Agreement, which involves a repricing of its senior secured term loan facility and an incremental borrowing of $250 million. The proceeds from this borrowing were used to repay a portion of its outstanding senior secured term loans, potentially impacting the company’s financial flexibility and stakeholder interests.
The most recent analyst rating on (DVA) stock is a Sell with a $145.00 price target. To see the full list of analyst forecasts on DaVita stock, see the DVA Stock Forecast page.
Spark’s Take on DVA Stock
According to Spark, TipRanks’ AI Analyst, DVA is a Outperform.
DaVita receives an overall score of 70, driven by strong financial performance in terms of revenue growth and cash flow management. The company’s strategic handling of recent challenges, such as the cybersecurity incident and treatment volume declines, also support a positive outlook. However, high leverage and negative equity pose financial risks. The technical analysis shows mixed signals, and while the P/E ratio suggests fair valuation, the lack of dividend yield may deter income-focused investors.
To see Spark’s full report on DVA stock, click here.
More about DaVita
DaVita Inc. operates in the healthcare industry, primarily providing kidney care services, including dialysis treatments. The company focuses on delivering high-quality care to patients with chronic kidney disease and end-stage renal disease.
Average Trading Volume: 810,469
Technical Sentiment Signal: Buy
Current Market Cap: $10.61B
For a thorough assessment of DVA stock, go to TipRanks’ Stock Analysis page.